Showing results (51-60 of 60) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Plos One|August 15, 2014
Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell helpArta M Monjazeb, Julia K Tietze, Steven K Grossenbacher, et al.Cancer Immunology, Immunotherapy : CII|June 14, 2016
Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysisMarkus V Heppt, Thomas K Eigentler, Katharina C Kähler, et al.European Journal of Cancer (Oxford, England : 1990)|April 23, 2024
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitorsTheresa Ruf, Rafaela Kramer, Andrea Forschner, et al.Blood|January 19, 2012
Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapyJulia K Tietze, Danice E C Wilkins, Gail D Sckisel, et al.Oncotarget|October 23, 2018
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter studyJulia K Tietze, Andrea Forschner, Carmen Loquai, et al.European Journal of Cancer (Oxford, England : 1990)|June 11, 2017
Prognostic factors and treatment outcomes in 444 patients with mucosal melanomaMarkus V Heppt, Alexander Roesch, Benjamin Weide, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibitionMarkus V Heppt, Lucie Heinzerling, Katharina C Kähler, et al.European Journal of Cancer (Oxford, England : 1990)|April 17, 2016
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapyLisa Zimmer, Simone M Goldinger, Lars Hofmann, et al.European Journal of Cancer (Oxford, England : 1990)|April 18, 2016
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapyLars Hofmann, Andrea Forschner, Carmen Loquai, et al.Pageof 6